title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20241216T210500,https://www.globenewswire.com/news-release/2024/12/16/2997877/0/en/Annexon-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.582526,Somewhat-Bullish,0.209562
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin  ( IVIg )  or Plasma Exchange  ( PE )  in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome  ( GBS ) ,20241216T123000,https://www.globenewswire.com/news-release/2024/12/16/2997418/0/en/Annexon-Announces-Positive-Topline-Results-from-Real-World-Evidence-Study-Comparing-ANX005-Treatment-to-Intravenous-Immunoglobulin-IVIg-or-Plasma-Exchange-PE-in-a-Matched-Patient-C.html,ANNX,0.157483,Neutral,0.074081
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20241115T215900,https://www.globenewswire.com/news-release/2024/11/15/2982269/0/en/Annexon-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.577527,Somewhat-Bullish,0.264443
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting - Annexon  ( NASDAQ:ANNX ) ,20241022T000041,https://www.benzinga.com/pressreleases/24/10/g41442047/annexon-presents-phase-2-vision-preservation-data-with-anx007-in-dry-amd-patients-with-less-advanc,ANNX,0.137018,Neutral,0.146559
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting,20241022T000000,https://www.globenewswire.com/news-release/2024/10/22/2966592/0/en/Annexon-Presents-Phase-2-Vision-Preservation-Data-with-ANX007-in-Dry-AMD-Patients-with-Less-Advanced-GA-at-the-American-Academy-of-Ophthalmology-2024-Meeting.html,ANNX,0.093653,Neutral,0.121422
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress - Annexon  ( NASDAQ:ANNX ) ,20240909T120000,https://www.benzinga.com/pressreleases/24/09/g40770858/annexon-to-present-phase-2-archer-data-on-protection-of-vision-and-photoreceptors-with-anx007-in-g,ANNX,0.181819,Neutral,0.09295
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20240816T200500,https://www.globenewswire.com/news-release/2024/08/16/2931713/0/en/Annexon-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.721785,Somewhat-Bullish,0.325401
Is Arbutus Biopharma  ( ABUS )  Outperforming Other Medical Stocks This Year?,20240806T134012,https://www.zacks.com/stock/news/2316975/is-arbutus-biopharma-abus-outperforming-other-medical-stocks-this-year,ANNX,0.478494,Somewhat-Bullish,0.21659
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20240716T200500,https://www.globenewswire.com/news-release/2024/07/16/2914149/0/en/Annexon-Reports-Inducement-Grant-to-New-Employee-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.730535,Somewhat-Bullish,0.31295
Is CareCloud  ( CCLD )  Outperforming Other Medical Stocks This Year?,20240715T134009,https://www.zacks.com/stock/news/2301597/is-carecloud-ccld-outperforming-other-medical-stocks-this-year,ANNX,0.464633,Somewhat-Bullish,0.278834
"Bank of New York Mellon Posts Upbeat Earnings, Joins Archer Aviation, Rivian Automotive And Other Big Stocks Moving Higher On Friday - Bank of New York Mellon  ( NYSE:BK ) ",20240712T142717,https://www.benzinga.com/news/24/07/39750475/bank-of-new-york-mellon-posts-upbeat-earnings-joins-archer-aviation-rivian-automotive-and-other-big,ANNX,0.175221,Bullish,0.469252
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting - Annexon  ( NASDAQ:ANNX ) ,20240711T220909,https://www.benzinga.com/pressreleases/24/07/g39740960/annexon-to-present-additional-phase-2-data-showing-preservation-of-visual-function-and-structure-b,ANNX,0.170275,Neutral,-0.014443
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting,20240711T220900,https://www.globenewswire.com/news-release/2024/07/11/2912176/0/en/Annexon-to-Present-Additional-Phase-2-Data-Showing-Preservation-of-Visual-Function-and-Structure-by-ANX007-in-Geographic-Atrophy-at-the-42nd-ASRS-Annual-Scientific-Meeting.html,ANNX,0.154455,Neutral,-0.013547
Are Medical Stocks Lagging Annexon  ( ANNX )  This Year?,20240628T134011,https://www.zacks.com/stock/news/2294956/are-medical-stocks-lagging-annexon-annx-this-year,ANNX,0.731515,Bullish,0.352486
Here's Why Annexon  ( ANNX )  Is a Great 'Buy the Bottom' Stock Now,20240627T135502,https://www.zacks.com/stock/news/2294368/heres-why-annexon-annx-is-a-great-buy-the-bottom-stock-now,ANNX,0.414559,Bullish,0.405734
Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors,20240627T124955,https://www.benzinga.com/pressreleases/24/06/g39524015/treating-geographic-atrophy-remains-a-tough-call-for-ophthalmologists-as-they-voice-hesitancy-to-p,ANNX,0.045396,Somewhat-Bullish,0.21708
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting,20240625T210000,https://www.globenewswire.com/news-release/2024/06/25/2904155/0/en/Annexon-Presented-Additional-Positive-Phase-3-Results-for-ANX005-C1q-Targeted-Immunotherapy-in-Guillain-Barr%C3%A9-Syndrome-at-the-2024-PNS-Annual-Meeting.html,ANNX,0.13994,Neutral,0.148288
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting - Annexon  ( NASDAQ:ANNX ) ,20240618T120000,https://www.benzinga.com/pressreleases/24/06/g39376518/annexon-to-present-pivotal-phase-3-data-on-early-and-durable-benefits-with-first-in-class-c1q-bloc,ANNX,0.244415,Neutral,-0.015175
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20240617T200500,https://www.globenewswire.com/news-release/2024/06/17/2900001/0/en/Annexon-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.721785,Somewhat-Bullish,0.22225
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Annexon  ( NASDAQ:ANNX ) ,20240617T200500,https://www.benzinga.com/pressreleases/24/06/g39365762/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4,ANNX,0.666827,Somewhat-Bullish,0.207367
Is Annexon  ( ANNX )  Stock Outpacing Its Medical Peers This Year?,20240607T134009,https://www.zacks.com/stock/news/2285310/is-annexon-annx-stock-outpacing-its-medical-peers-this-year,ANNX,0.747404,Somewhat-Bullish,0.332081
Annexon Announces Pricing of $125 Million Underwritten Public Offering,20240606T033231,https://investingnews.com/annexon-announces-pricing-of-125-million-underwritten-public-offering/,ANNX,0.388879,Somewhat-Bullish,0.173168
Annexon Announces Pricing of $125 Million Underwritten Public Offering,20240606T030400,https://www.globenewswire.com/news-release/2024/06/06/2894382/0/en/Annexon-Announces-Pricing-of-125-Million-Underwritten-Public-Offering.html,ANNX,0.388209,Somewhat-Bullish,0.175606
Annexon  ( ANNX )  Up as Phase III Neuro Disorder Study Meets Goals,20240605T145700,https://www.zacks.com/stock/news/2284172/annexon-annx-up-as-phase-iii-neuro-disorder-study-meets-goals,ANNX,0.43082,Somewhat-Bullish,0.217857
Wall Street Analysts Think Annexon  ( ANNX )  Could Surge 133.72%: Read This Before Placing a Bet,20240605T135506,https://www.zacks.com/stock/news/2283995/wall-street-analysts-think-annexon-annx-could-surge-13372-read-this-before-placing-a-bet,ANNX,0.2842,Somewhat-Bullish,0.303521
"DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - DouYu Intl Hldgs  ( NASDAQ:DOYU ) ",20240605T120739,https://www.benzinga.com/news/24/06/39181909/douyu-international-posts-q1-results-joins-annexon-dollar-tree-and-other-big-stocks-moving-lower-in,ANNX,0.268294,Neutral,-0.068357
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Stitch Fix  ( NASDAQ:SFIX ) ,20240605T092725,https://www.benzinga.com/news/24/06/39178410/why-stitch-fix-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket,ANNX,0.140896,Neutral,-0.042634
Annexon Announces Proposed Public Offering of Common Stock,20240604T210600,https://www.globenewswire.com/news-release/2024/06/04/2893486/0/en/Annexon-Announces-Proposed-Public-Offering-of-Common-Stock.html,ANNX,0.356225,Neutral,0.105318
Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings - Designer Brands  ( NYSE:DBI ) ,20240604T183230,https://www.benzinga.com/news/earnings/24/06/39168394/dow-surges-200-points-designer-brands-shares-plunge-following-q1-earnings,ANNX,0.145145,Somewhat-Bullish,0.249592
Why is Annexon Stock Trading Higher On Tuesday? - Annexon  ( NASDAQ:ANNX ) ,20240604T160620,https://www.benzinga.com/general/biotech/24/06/39165249/mid-cap-firm-annexons-nerve-disorder-candidate-shows-promise-in-pivotal-late-stage-study,ANNX,0.401331,Neutral,-0.1234
"Saia, Annexon, Core Scientific And Other Big Stocks Moving Higher On Tuesday - Saia  ( NASDAQ:SAIA ) ",20240604T140859,https://www.benzinga.com/news/24/06/39161979/saia-annexon-core-scientific-and-other-big-stocks-moving-higher-on-tuesday,ANNX,0.305058,Neutral,0.0
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome - Annexon  ( NASDAQ:ANNX ) ,20240604T110000,https://www.benzinga.com/pressreleases/24/06/g39155240/annexon-announces-positive-topline-results-from-pivotal-phase-3-trial-for-first-in-class-c1q-block,ANNX,0.208614,Neutral,0.075909
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - HealthEquity  ( NASDAQ:HQY ) ,20240604T095006,https://www.benzinga.com/news/24/06/39153820/why-healthequity-shares-are-trading-higher-here-are-20-stocks-moving-premarket,ANNX,0.190167,Neutral,0.126493
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data,20240603T203000,https://www.globenewswire.com/news-release/2024/06/03/2892620/0/en/Annexon-Biosciences-to-Host-Conference-Call-and-Webcast-to-Discuss-GBS-Phase-3-Data.html,ANNX,0.648497,Somewhat-Bearish,-0.172286
Is Avalo Therapeutics  ( AVTX )  Stock Outpacing Its Medical Peers This Year?,20240522T134009,https://www.zacks.com/stock/news/2277231/is-avalo-therapeutics-avtx-stock-outpacing-its-medical-peers-this-year,ANNX,0.478494,Bullish,0.350218
"Annexon  ( ANNX )  Loses -5.04% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner",20240520T133506,https://www.zacks.com/stock/news/2275982/annexon-annx-loses--504-in-4-weeks-heres-why-a-trend-reversal-may-be-around-the-corner,ANNX,0.483888,Somewhat-Bullish,0.233263
Annexon Biosciences to Present at the Bank of America Health Care Conference,20240509T120000,https://www.globenewswire.com/news-release/2024/05/09/2878698/0/en/Annexon-Biosciences-to-Present-at-the-Bank-of-America-Health-Care-Conference.html,ANNX,0.81111,Neutral,0.024578
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting,20240507T163000,https://www.globenewswire.com/news-release/2024/05/07/2877044/0/en/Annexon-Presents-New-Neuroprotection-Data-Showing-ANX007-Protects-Vision-and-Vision-Associated-Structures-in-Geographic-Atrophy-at-ARVO-2024-Annual-Meeting.html,ANNX,0.180236,Neutral,0.059932
RevOpsis Welcomes Dr. Emmett Cunningham to Strategic Advisory Board,20240503T140000,https://www.prnewswire.com/news-releases/revopsis-welcomes-dr-emmett-cunningham-to-strategic-advisory-board-302135444.html,ANNX,0.050359,Somewhat-Bullish,0.310617
Annexon  ( ANNX )  to Report Q1 Earnings: What's in the Cards?,20240501T141500,https://www.zacks.com/stock/news/2266131/annexon-annx-to-report-q1-earnings-whats-in-the-cards,ANNX,0.547615,Somewhat-Bullish,0.219063
"Down -43.02% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon  ( ANNX ) ",20240425T133506,https://www.zacks.com/stock/news/2262171/down--4302-in-4-weeks-heres-why-you-should-you-buy-the-dip-in-annexon-annx,ANNX,0.495015,Somewhat-Bullish,0.17936
Are Medical Stocks Lagging Annexon  ( ANNX )  This Year?,20240417T134010,https://www.zacks.com/stock/news/2256801/are-medical-stocks-lagging-annexon-annx-this-year,ANNX,0.78028,Bullish,0.450364
"Annexon, Inc.  ( ANNX )  Falls More Steeply Than Broader Market: What Investors Need to Know",20240410T221519,https://www.zacks.com/stock/news/2253705/annexon-inc-annx-falls-more-steeply-than-broader-market-what-investors-need-to-know,ANNX,0.53784,Somewhat-Bullish,0.232002
What Makes Annexon  ( ANNX )  a New Buy Stock,20240401T160009,https://www.zacks.com/stock/news/2248586/what-makes-annexon-annx-a-new-buy-stock,ANNX,0.367865,Bullish,0.3597
Wall Street Analysts Believe Annexon  ( ANNX )  Could Rally 101.12%: Here's is How to Trade,20240401T135505,https://www.zacks.com/stock/news/2248420/wall-street-analysts-believe-annexon-annx-could-rally-10112-heres-is-how-to-trade,ANNX,0.2842,Somewhat-Bullish,0.303521
"Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday - Cintas  ( NASDAQ:CTAS ) , Noah Holdings  ( NYSE:NOAH ) , PaySign  ( NASDAQ:PAYS ) ",20240327T140327,https://www.benzinga.com/news/24/03/37959584/cintas-reports-upbeat-earnings-joins-paysign-noah-holdings-and-other-big-stocks-moving-higher-on-wed,ANNX,0.202366,Bullish,0.376038
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones,20240326T200500,https://www.globenewswire.com/news-release/2024/03/26/2852727/0/en/Annexon-Reports-Fourth-Quarter-and-Year-End-2023-Financial-Results-and-Key-Anticipated-Milestones.html,ANNX,0.159437,Neutral,0.0503
"Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday - FedEx  ( NYSE:FDX ) , Worthington Steel  ( NYSE:WS ) ",20240322T140847,https://www.benzinga.com/news/24/03/37891941/worthington-steel-posts-upbeat-results-joins-summit-midstream-partners-fedex-and-other-big-stocks-mo,ANNX,0.21686,Neutral,0.0
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Annexon  ( NASDAQ:ANNX ) ,20240318T200500,https://www.benzinga.com/pressreleases/24/03/g37799983/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4,ANNX,0.759278,Somewhat-Bullish,0.270148
Why Annexon  ( ANNX )  Might Surprise This Earnings Season,20240314T124000,https://www.zacks.com/stock/news/2240542/why-annexon-annx-might-surprise-this-earnings-season,ANNX,0.898858,Bullish,0.542427
ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer,20240122T130000,https://www.prnewswire.com/news-releases/immunobrain-checkpoint-appoints-dr-sanjay-keswani-as-chief-executive-officer-302039635.html,ANNX,0.065685,Neutral,0.085332
"Take the Zacks Approach to Beat the Market: Annexon, NVIDIA, Intuit in Focus",20240122T115800,https://www.zacks.com/stock/news/2213270/take-the-zacks-approach-to-beat-the-market-annexon-nvidia-intuit-in-focus,ANNX,0.067158,Somewhat-Bullish,0.253167
Is Annexon  ( ANNX )  Stock Outpacing Its Medical Peers This Year?,20240118T144003,https://www.zacks.com/stock/news/2212118/is-annexon-annx-stock-outpacing-its-medical-peers-this-year,ANNX,0.745397,Bullish,0.419867
Annexon  ( ANNX )  Stock Rallies 156% in 3 Months: Here's How,20240117T160600,https://www.zacks.com/stock/news/2211545/annexon-annx-stock-rallies-156-in-3-months-heres-how,ANNX,0.498987,Somewhat-Bullish,0.300461
"Harpoon Therapeutics, Heron Therapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session - Altimmune  ( NASDAQ:ALT ) , Annexon  ( NASDAQ:ANNX ) ",20240108T103728,https://www.benzinga.com/news/24/01/36529043/harpoon-therapeutics-heron-therapeutics-and-other-big-stocks-moving-higher-in-mondays-pre-market-ses,ANNX,0.465196,Bullish,0.421938
"Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases - Annexon  ( NASDAQ:ANNX ) ",20240108T010005,https://www.benzinga.com/pressreleases/24/01/g36526959/annexon-outlines-2024-priorities-with-late-stage-clinical-milestones-across-upstream-complement-po,ANNX,0.383616,Neutral,0.114677
"Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases",20240108T010000,https://www.globenewswire.com/news-release/2024/01/08/2805026/0/en/Annexon-Outlines-2024-Priorities-with-Late-Stage-Clinical-Milestones-Across-Upstream-Complement-Portfolio-for-Autoimmune-Ophthalmic-and-Neurodegenerative-Diseases.html,ANNX,0.377142,Somewhat-Bullish,0.161005
"US Neurologists Optimistic Regarding the Huntington's Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority",20240103T144651,https://www.benzinga.com/pressreleases/24/01/g36470593/us-neurologists-optimistic-regarding-the-huntingtons-disease-treatment-pipeline-emphasizing-haltin,ANNX,0.04823,Neutral,0.057266
"$1M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying - SRAX  ( OTC:SRAX ) , Annexon  ( NASDAQ:ANNX ) ",20231229T113646,https://www.benzinga.com/trading-ideas/long-ideas/23/12/36424252/1m-bet-on-this-healthcare-stock-check-out-these-3-penny-stocks-insiders-are-aggressively,ANNX,0.570165,Somewhat-Bullish,0.307379
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference,20231227T113000,https://www.globenewswire.com/news-release/2023/12/27/2801303/0/en/Annexon-Biosciences-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,ANNX,0.899125,Neutral,-0.02527
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Annexon  ( NASDAQ:ANNX ) ,20231227T113000,https://www.benzinga.com/pressreleases/23/12/g36394912/annexon-biosciences-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference,ANNX,0.844077,Neutral,-0.020609
"Nasdaq Gains 100 Points; CarMax Earnings Top Views - Clene  ( NASDAQ:CLNN ) , Annexon  ( NASDAQ:ANNX ) ",20231221T192303,https://www.benzinga.com/news/earnings/23/12/36350420/nasdaq-gains-100-points-carmax-earnings-top-views,ANNX,0.244723,Neutral,0.140637
Why Is Complement-Mediated Focused Annexon Stock Trading Higher Today? - Annexon  ( NASDAQ:ANNX ) ,20231221T160718,https://www.benzinga.com/general/biotech/23/12/36342487/why-is-complement-mediated-focused-annexon-stock-trading-higher-today,ANNX,0.647216,Neutral,0.147927
"Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway",20231221T001907,https://markets.businessinsider.com/news/stocks/annexon-reports-phase-1-results-for-anx1502-its-oral-small-molecule-inhibitor-of-the-classical-complement-pathway-1032917565,ANNX,0.309973,Somewhat-Bullish,0.155656
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock,20231220T222700,https://www.globenewswire.com/news-release/2023/12/20/2799681/0/en/Annexon-Announces-Pricing-of-125-0-Million-Underwritten-Public-Offering-of-Common-Stock.html,ANNX,0.490323,Neutral,0.078557
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint - Annexon  ( NASDAQ:ANNX ) ,20231220T221053,https://www.benzinga.com/pressreleases/23/12/g36335370/annexon-outlines-global-registrational-program-for-anx007-in-geographic-atrophy-with-fda-alignment,ANNX,0.198873,Neutral,0.091041
Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint,20231220T221000,https://www.globenewswire.com/news-release/2023/12/20/2799678/0/en/Annexon-Outlines-Global-Registrational-Program-for-ANX007-in-Geographic-Atrophy-with-FDA-Alignment-on-Vision-Preservation-as-Primary-Endpoint.html,ANNX,0.222096,Neutral,0.128505
"Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement Pathway",20231220T220800,https://www.globenewswire.com/news-release/2023/12/20/2799677/0/en/Annexon-Reports-Phase-1-Results-for-ANX1502-its-Oral-Small-Molecule-Inhibitor-of-the-Classical-Complement-Pathway.html,ANNX,0.28387,Neutral,0.149929
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20231218T210100,https://www.globenewswire.com/news-release/2023/12/18/2798116/0/en/Annexon-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.805127,Somewhat-Bullish,0.272456
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference,20231122T210100,https://www.globenewswire.com/news-release/2023/11/22/2785030/0/en/Annexon-Biosciences-to-Participate-in-the-6th-Annual-Evercore-ISI-HealthCONx-Conference.html,ANNX,0.896455,Neutral,-0.025237
Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference - Annexon  ( NASDAQ:ANNX ) ,20231122T210100,https://www.benzinga.com/pressreleases/23/11/g35924972/annexon-biosciences-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference,ANNX,0.87744,Neutral,-0.02088
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results,20231113T113000,https://www.globenewswire.com/news-release/2023/11/13/2778849/0/en/Annexon-Reports-Significant-Progress-with-its-Priority-Programs-and-Third-Quarter-2023-Financial-Results.html,ANNX,0.240291,Neutral,0.148292
Annexon Biosciences to Participate in 2023 Jefferies London Healthcare Conference,20231109T113000,https://www.globenewswire.com/news-release/2023/11/09/2777120/0/en/Annexon-Biosciences-to-Participate-in-2023-Jefferies-London-Healthcare-Conference.html,ANNX,0.90178,Neutral,0.062878
Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic Atrophy,20231024T103000,https://www.globenewswire.com/news-release/2023/10/24/2765415/0/en/Annexon-Receives-PRIME-Designation-from-the-EMA-for-ANX007-for-the-Treatment-of-Geographic-Atrophy.html,ANNX,0.222582,Neutral,0.139941
"Open-Angle Glaucoma Market Size and Share to Accelerate Substantially by 2032, Predicts DelveInsight | Key Companies in the Market - SPARC, AbbVie, Ocuphire, Santen, Glaukos, Ocular Therapeutix, VivaVision Biotech, MediPrint Ophthalmics",20231012T210100,https://www.prnewswire.com/news-releases/open-angle-glaucoma-market-size-and-share-to-accelerate-substantially-by-2032-predicts-delveinsight--key-companies-in-the-market---sparc-abbvie-ocuphire-santen-glaukos-ocular-therapeutix-vivavision-biotech-mediprint-ophth-301954523.html,ANNX,0.025651,Neutral,0.036754
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome  ( GBS ) ,20231010T103000,https://www.globenewswire.com/news-release/2023/10/10/2757271/0/en/Annexon-Announces-Clinical-and-Regulatory-Progress-for-ANX005-Pivotal-Program-in-Guillain-Barr%C3%A9-Syndrome-GBS.html,ANNX,0.216215,Neutral,0.012224
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference,20230919T103000,https://www.globenewswire.com/news-release/2023/09/19/2745419/0/en/Annexon-Biosciences-to-Participate-in-the-2023-Cantor-Global-Healthcare-Conference.html,ANNX,0.880186,Somewhat-Bullish,0.269991
Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare Conference - Annexon  ( NASDAQ:ANNX ) ,20230919T103000,https://www.benzinga.com/pressreleases/23/09/g34720671/annexon-biosciences-to-participate-in-the-2023-cantor-global-healthcare-conference,ANNX,0.860826,Somewhat-Bullish,0.268003
"Down -28.96% in 4 Weeks, Here's Why You Should You Buy the Dip in Annexon, Inc.  ( ANNX ) ",20230908T133506,https://www.zacks.com/stock/news/2146543/down--2896-in-4-weeks-heres-why-you-should-you-buy-the-dip-in-annexon-inc-annx,ANNX,0.483888,Somewhat-Bullish,0.284173
InflaRx  ( IFRX )  Skyrockets 110% in Six Months: Here's Why,20230901T183800,https://www.zacks.com/stock/news/2143927/inflarx-ifrx-skyrockets-110-in-six-months-heres-why,ANNX,0.236972,Neutral,0.09091
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results,20230807T103000,https://www.globenewswire.com/news-release/2023/08/07/2719531/0/en/Annexon-Highlights-Recent-Pipeline-and-Business-Progress-and-Reports-Second-Quarter-2023-Financial-Results.html,ANNX,0.331765,Neutral,0.127536
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Annexon  ( NASDAQ:ANNX ) ,20230802T200100,https://www.benzinga.com/pressreleases/23/08/g33530872/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4,ANNX,0.746257,Bullish,0.518349
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy,20230730T160000,https://www.globenewswire.com/news-release/2023/07/30/2714521/0/en/Annexon-Presents-ARCHER-Trial-Results-at-ASRS-2023-Highlighting-Potential-of-ANX007-as-a-Differentiated-Treatment-for-Geographic-Atrophy.html,ANNX,0.267664,Neutral,0.037246
Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy - Annexon  ( NASDAQ:ANNX ) ,20230730T160000,https://www.benzinga.com/pressreleases/23/07/g33460789/annexon-presents-archer-trial-results-at-asrs-2023-highlighting-potential-of-anx007-as-a-different,ANNX,0.226477,Neutral,0.08008
"Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer",20230727T103000,https://www.globenewswire.com/news-release/2023/07/27/2711977/0/en/Annexon-Biosciences-Strengthens-Leadership-Team-with-Appointment-of-Jamie-Dananberg-M-D-as-Chief-Medical-Officer.html,ANNX,0.692465,Bullish,0.375752
"Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer - Annexon  ( NASDAQ:ANNX ) ",20230727T103000,https://www.benzinga.com/pressreleases/23/07/g33414017/annexon-biosciences-strengthens-leadership-team-with-appointment-of-jamie-dananberg-m-d-as-chief-m,ANNX,0.630286,Bullish,0.357439
Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023,20230724T103000,https://www.globenewswire.com/news-release/2023/07/24/2709360/0/en/Annexon-to-Report-ARCHER-Phase-2-Trial-Results-in-Geographic-Atrophy-at-ASRS-2023.html,ANNX,0.822984,Somewhat-Bullish,0.167853
"Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain - Novartis, Annexon, Apellis, Ionis, Astellas, Gyroscope, Genentech, Aviceda, Iveric Bio",20230628T210100,https://www.prnewswire.com/news-releases/geographic-atrophy-market-to-boost-significantly-assesses-delveinsight--key-companies-active-in-the-domain---novartis-annexon-apellis-ionis-astellas-gyroscope-genentech-aviceda-iveric-bio-301865699.html,ANNX,0.077426,Neutral,-0.01029
Annexon  ( ANNX )  Stock Down More Than 50% Last Week: Here's Why,20230530T144000,https://www.zacks.com/stock/news/2101444/annexon-annx-stock-down-more-than-50-last-week-heres-why,ANNX,0.303175,Neutral,-0.085406
"Crude Oil Drops Sharply; Best Buy Earnings Top Expectations - Annexon  ( NASDAQ:ANNX ) , Digital Turbine  ( NASDAQ:APPS ) ",20230525T183908,https://www.benzinga.com/news/earnings/23/05/32582243/crude-oil-drops-sharply-best-buy-earnings-top-expectations,ANNX,0.1172,Neutral,0.00807
"Nasdaq Surges 1.5%; NVIDIA Shares Jump Following Strong Q1 Results - Annexon  ( NASDAQ:ANNX ) , Digital Turbine  ( NASDAQ:APPS ) ",20230525T160218,https://www.benzinga.com/news/earnings/23/05/32579047/nasdaq-surges-1-5-nvidia-shares-jump-following-strong-q1-results,ANNX,0.115787,Neutral,0.008028
Why Shares of Annexon Are Plummeting Thursday,20230525T155231,https://www.fool.com/investing/2023/05/25/why-shares-of-annexon-are-plummeting-thursday/,ANNX,0.47672,Somewhat-Bullish,0.320793
Why Annexon  ( ANNX )  Stock Is Getting Hammered - Annexon  ( NASDAQ:ANNX ) ,20230525T153507,https://www.benzinga.com/news/23/05/32576633/why-annexon-annx-stock-is-getting-hammered,ANNX,0.925854,Neutral,0.0
"Dow Drops 100 Points; US GDP Tops Estimates - Annexon  ( NASDAQ:ANNX ) , Digital Turbine  ( NASDAQ:APPS ) ",20230525T134627,https://www.benzinga.com/news/earnings/23/05/32574777/dow-drops-100-points-us-gdp-tops-estimates,ANNX,0.131284,Neutral,0.008523
Why Annexon  ( ANNX )  Stock Is Tumbling Today - Annexon  ( NASDAQ:ANNX ) ,20230525T121227,https://www.benzinga.com/general/biotech/23/05/32568850/annexons-eye-disease-drug-reports-mixed-trial-results-will-focus-on-planned-late-stage-study,ANNX,0.740604,Somewhat-Bearish,-0.157162
Annexon Biosciences to Participate in the 22nd Annual Needham Virtual Healthcare Conference,20230411T103000,https://www.globenewswire.com/news-release/2023/04/11/2644185/0/en/Annexon-Biosciences-to-Participate-in-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html,ANNX,0.874686,Bullish,0.35742
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones,20230306T113000,https://www.globenewswire.com/news-release/2023/03/06/2620852/0/en/Annexon-Reports-Fourth-Quarter-and-Year-End-2022-Financial-Results-and-Reiterates-Anticipated-Milestones.html,ANNX,0.366061,Neutral,0.130637
Annexon Biosciences to Participate in the 43rd Annual Cowen Healthcare Conference,20230227T113000,https://www.globenewswire.com/news-release/2023/02/27/2615857/0/en/Annexon-Biosciences-to-Participate-in-the-43rd-Annual-Cowen-Healthcare-Conference.html,ANNX,0.874686,Bullish,0.353806
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Annexon  ( NASDAQ:ANNX ) ,20230216T210500,https://www.benzinga.com/pressreleases/23/02/g30950897/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4,ANNX,0.746257,Bullish,0.483172
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20230117T213000,https://www.globenewswire.com/news-release/2023/01/17/2590531/0/en/Annexon-Reports-Inducement-Grant-to-New-Employee-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.748842,Bullish,0.51896
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20230117T213000,https://www.benzinga.com/pressreleases/23/01/g30451541/annexon-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635-c-4,ANNX,0.730954,Bullish,0.50599
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises,20230108T140000,https://www.globenewswire.com/news-release/2023/01/08/2584729/0/en/Annexon-Highlights-Strategic-Focus-to-Advance-Four-Flagship-Complement-Programs-through-Late-Stage-Development-and-Progress-Across-Three-Therapeutic-Franchises.html,ANNX,0.372027,Neutral,0.148518
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises - Annexon  ( NASDAQ:ANNX ) ,20230108T140000,https://www.benzinga.com/pressreleases/23/01/g30323708/annexon-highlights-strategic-focus-to-advance-four-flagship-complement-programs-through-late-stage,ANNX,0.352223,Somewhat-Bullish,0.181715
"Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio",20230106T113000,https://www.globenewswire.com/news-release/2023/01/06/2584298/0/en/Annexon-Appoints-Industry-Veteran-Dr-Rick-Artis-as-Chief-Scientific-Officer-to-Support-the-Advancement-and-Expansion-of-Complement-focused-Portfolio.html,ANNX,0.68145,Bullish,0.493496
"Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio - Annexon  ( NASDAQ:ANNX ) ",20230106T113000,https://www.benzinga.com/pressreleases/23/01/g30307799/annexon-appoints-industry-veteran-dr-rick-artis-as-chief-scientific-officer-to-support-the-advance,ANNX,0.672864,Bullish,0.488192
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference,20230104T113000,https://www.globenewswire.com/news-release/2023/01/04/2582723/0/en/Annexon-to-Present-at-41st-Annual-J-P-Morgan-Healthcare-Conference.html,ANNX,0.874686,Bullish,0.35742
Annexon to Present at 41st Annual J.P. Morgan Healthcare Conference - Annexon  ( NASDAQ:ANNX ) ,20230104T113000,https://www.benzinga.com/pressreleases/23/01/g30270433/annexon-to-present-at-41st-annual-j-p-morgan-healthcare-conference,ANNX,0.855251,Bullish,0.351275
"Wall Street Analysts Think Annexon, Inc.  ( ANNX )  Could Surge 241%: Read This Before Placing a Bet",20221201T145527,https://www.zacks.com/stock/news/2024227/wall-street-analysts-think-annexon-inc-annx-could-surge-241-read-this-before-placing-a-bet,ANNX,0.284861,Bullish,0.366893
"How Much Upside is Left in Annexon, Inc.  ( ANNX ) ? Wall Street Analysts Think 246%",20221115T145516,https://www.zacks.com/stock/news/2018429/how-much-upside-is-left-in-annexon-inc-annx-wall-street-analysts-think-246,ANNX,0.286864,Bullish,0.359395
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023,20221103T103000,https://www.globenewswire.com/news-release/2022/11/03/2547351/0/en/Annexon-Reports-Third-Quarter-2022-Financial-Results-and-Plans-to-Provide-Updates-on-Complement-Therapeutic-Portfolio-in-January-2023.html,ANNX,0.340194,Somewhat-Bullish,0.228482
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220916T200100,https://www.globenewswire.com/news-release/2022/09/16/2517825/0/en/Annexon-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.767202,Bullish,0.49683
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 )  - Annexon  ( NASDAQ:ANNX ) ,20220916T200100,https://www.benzinga.com/pressreleases/22/09/g28902001/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4,ANNX,0.748842,Bullish,0.483733
BioCryst Pharmaceuticals  ( NASDAQ:BCRX )  - BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer,20220914T200110,https://www.benzinga.com/pressreleases/22/09/g28872104/biocryst-names-dr-bill-sheridan-chief-development-officer-and-appoints-dr-ryan-arnold-chief-medica,ANNX,0.06623,Neutral,0.044129
BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer,20220914T200100,https://www.globenewswire.com/news-release/2022/09/14/2516384/29446/en/BioCryst-Names-Dr-Bill-Sheridan-Chief-Development-Officer-and-Appoints-Dr-Ryan-Arnold-Chief-Medical-Officer.html,ANNX,0.069697,Neutral,0.045268
Co. Advancing Drug Class With Broad Potential,20220914T160429,https://www.investorideas.com/news/2022/biotech/09142Advancing-Drug-Class.asp,ANNX,0.083687,Neutral,-0.034947
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220817T200500,https://www.globenewswire.com/news-release/2022/08/17/2500377/0/en/Annexon-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html,ANNX,0.775204,Bullish,0.483492
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220817T200500,https://www.benzinga.com/pressreleases/22/08/g28541480/annexon-reports-inducement-grants-to-new-employees-under-nasdaq-listing-rule-5635-c-4,ANNX,0.471718,Bullish,0.374621
ANNX: Insider Buying Sends Annexon Stock Higher. But Does That Make It a Buy?,20220721T131546,https://stocknews.com/news/annx-vrtx-amgn-biib-insider-buying-sends-annexon-stock-higher-but-does-that-make/,ANNX,0.740328,Somewhat-Bullish,0.27022
ANNX: 4 Penny Stocks to Target Following the Latest Jobs Report,20220714T144552,https://stocknews.com/news/annx-apre-ysg-endp-4-penny-stocks-to-target-following-the-latest-jobs-report/,ANNX,0.280615,Neutral,0.147796
"The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner",20220712T130420,https://www.benzinga.com/general/biotech/22/07/28031430/the-daily-biotech-pulse-gsk-to-supply-50m-flu-vaccine-doses-to-us-fda-lifts-hold-on-greenwichs-ca,ANNX,0.115232,Neutral,0.115886
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025,20220711T222500,https://www.globenewswire.com/news-release/2022/07/11/2477683/0/en/Annexon-Closes-130-Million-Private-Placement-Extending-its-Operating-Runway-into-the-Second-Half-of-2025.html,ANNX,0.381861,Somewhat-Bullish,0.305135
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025,20220711T222500,https://www.benzinga.com/pressreleases/22/07/g28026055/annexon-closes-130-million-private-placement-extending-its-operating-runway-into-the-second-half-o,ANNX,0.378181,Somewhat-Bullish,0.300703
"Tesla, Twitter And 76 Biggest Movers From Friday",20220711T113029,https://www.benzinga.com/news/22/07/28014980/tesla-twitter-and-76-biggest-movers-from-friday,ANNX,0.056741,Neutral,0.139954
Best Penny Stocks To Buy Now? 4 To Watch After Jobs Report,20220708T143353,https://pennystocks.com/featured/2022/07/08/best-penny-stocks-buy-now-4-watch-jobs-report/,ANNX,0.116447,Somewhat-Bullish,0.2473
"The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug",20220708T121902,https://www.benzinga.com/general/biotech/22/07/27998206/the-daily-biotech-pulse-pfizer-inks-pact-with-africa-for-covid-19-pills-emergent-bio-ridgeback-to,ANNX,0.126985,Neutral,0.000447
Annexon Announces $130 Million Private Placement Financing,20220708T110000,https://www.globenewswire.com/news-release/2022/07/08/2476488/0/en/Annexon-Announces-130-Million-Private-Placement-Financing.html,ANNX,0.486054,Neutral,0.024683
Annexon Announces $130 Million Private Placement Financing,20220708T110000,https://www.benzinga.com/pressreleases/22/07/g27997941/annexon-announces-130-million-private-placement-financing,ANNX,0.4232,Neutral,0.026843
79 Biggest Movers From Yesterday,20220608T080800,https://www.benzinga.com/news/22/06/27602286/79-biggest-movers-from-yesterday,ANNX,0.090145,Neutral,-0.001855
Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues,20220607T161903,https://www.benzinga.com/general/biotech/22/06/27591329/annexon-touts-final-huntingtons-trial-data-confirming-no-new-safety-issues,ANNX,0.547593,Neutral,0.009164
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington's Disease,20220607T103000,https://www.globenewswire.com/news-release/2022/06/07/2457463/0/en/Annexon-Biosciences-Reports-Phase-2-Clinical-Trial-Results-Demonstrating-Upstream-Classical-Complement-Inhibition-Associated-with-Clinical-Benefit-in-Huntington-s-Disease.html,ANNX,0.189076,Somewhat-Bullish,0.213885
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference,20220602T103000,https://www.globenewswire.com/news-release/2022/06/02/2454978/0/en/Annexon-Biosciences-to-Present-at-the-2022-Jefferies-Healthcare-Conference.html,ANNX,0.820913,Neutral,0.059198
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference,20220602T103000,https://www.benzinga.com/pressreleases/22/06/g27517261/annexon-biosciences-to-present-at-the-2022-jefferies-healthcare-conference,ANNX,0.725852,Neutral,0.062903
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings,20220601T113000,https://www.globenewswire.com/news-release/2022/06/01/2454125/0/en/Annexon-Biosciences-to-Present-Data-Highlighting-Novel-Approach-to-Treating-Complement-Driven-Diseases-at-Upcoming-Medical-Meetings.html,ANNX,0.323184,Neutral,0.079376
103 Biggest Movers From Yesterday,20220511T102237,https://www.benzinga.com/news/22/05/27130447/103-biggest-movers-from-yesterday,ANNX,0.06399,Neutral,-0.035967
"ADCT Awaits Cami Trial Data, CSTL Boosts Revenue Outlook, ANNX To Report HD Trial Data In Q2",20220510T094515,https://markets.businessinsider.com/news/stocks/adct-awaits-cami-trial-data-cstl-boosts-revenue-outlook-annx-to-report-hd-trial-data-in-q2-1031440845,ANNX,0.065452,Neutral,0.125946
Annexon Biosciences to Participate in Upcoming May Investor Conferences,20220505T103000,https://www.benzinga.com/pressreleases/22/05/g27013929/annexon-biosciences-to-participate-in-upcoming-may-investor-conferences,ANNX,0.633388,Neutral,0.050372
53 Biggest Movers From Yesterday,20220421T085205,https://www.benzinga.com/news/22/04/26731039/53-biggest-movers-from-yesterday,ANNX,0.068836,Neutral,0.000828
What Are Penny Stocks? What You Need to Know and 3 to Watch,20220420T194134,https://pennystocks.com/featured/2022/04/20/what-are-penny-stocks-what-need-know-3-watch/,ANNX,0.128523,Neutral,0.125917
54 Biggest Movers From Yesterday,20220420T094334,https://www.benzinga.com/news/22/04/26706319/54-biggest-movers-from-yesterday,ANNX,0.103524,Neutral,0.00183
38 Stocks Moving In Tuesday's Mid-Day Session,20220419T161631,https://www.benzinga.com/news/22/04/26694580/38-stocks-moving-in-tuesdays-mid-day-session,ANNX,0.15119,Neutral,0.00042
23 Stocks Moving in Tuesday's Pre-Market Session,20220419T103745,https://www.benzinga.com/news/22/04/26682742/23-stocks-moving-in-tuesdays-pre-market-session,ANNX,0.190117,Neutral,0.000243
Stocks That Hit 52-Week Lows On Monday,20220418T154044,https://www.benzinga.com/news/22/04/26669813/stocks-that-hit-52-week-lows-on-monday,ANNX,0.005428,Neutral,-0.013213
Stocks That Hit 52-Week Lows On Friday,20220408T163534,https://www.benzinga.com/news/22/04/26547302/stocks-that-hit-52-week-lows-on-friday,ANNX,0.011399,Neutral,-0.005653
"Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy",20220407T103000,https://www.globenewswire.com/news-release/2022/04/07/2418284/0/en/Annexon-Biosciences-Completes-Enrollment-in-ARCHER-Phase-2-Trial-of-Novel-C1q-Inhibitor-ANX007-in-Patients-with-Geographic-Atrophy.html,ANNX,0.347432,Somewhat-Bullish,0.307787
Stocks That Hit 52-Week Lows On Monday,20220404T160501,https://www.benzinga.com/news/22/04/26453944/stocks-that-hit-52-week-lows-on-monday,ANNX,0.031491,Neutral,-0.008559
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference,20220404T103000,https://www.globenewswire.com/news-release/2022/04/04/2415510/0/en/Annexon-Biosciences-to-Participate-in-the-21st-Annual-Needham-Virtual-Healthcare-Conference.html,ANNX,0.702913,Neutral,0.034113
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference,20220404T103000,https://www.benzinga.com/pressreleases/22/04/g26444887/annexon-biosciences-to-participate-in-the-21st-annual-needham-virtual-healthcare-conference,ANNX,0.668612,Neutral,0.049633
Stocks That Hit 52-Week Lows On Friday,20220401T170001,https://www.benzinga.com/news/22/04/26425809/stocks-that-hit-52-week-lows-on-friday,ANNX,0.021113,Neutral,-0.026488
Stocks That Hit 52-Week Lows On Thursday,20220331T181044,https://www.benzinga.com/news/22/03/26401822/stocks-that-hit-52-week-lows-on-thursday,ANNX,0.02511,Neutral,-0.025102
Stocks That Hit 52-Week Lows On Wednesday,20220330T164203,https://www.benzinga.com/news/22/03/26376884/stocks-that-hit-52-week-lows-on-wednesday,ANNX,0.067177,Neutral,-0.027664
Stocks That Hit 52-Week Lows On Tuesday,20220329T154325,https://www.benzinga.com/news/22/03/26352676/stocks-that-hit-52-week-lows-on-tuesday,ANNX,0.027837,Neutral,-0.010405
Stocks That Hit 52-Week Lows On Monday,20220328T154408,https://www.benzinga.com/news/22/03/26326033/stocks-that-hit-52-week-lows-on-monday,ANNX,0.016131,Neutral,-0.050564
Stocks That Hit 52-Week Lows On Wednesday,20220323T154749,https://www.benzinga.com/news/22/03/26261101/stocks-that-hit-52-week-lows-on-wednesday,ANNX,0.03456,Neutral,-0.030484
Stocks That Hit 52-Week Lows On Tuesday,20220315T163235,https://www.benzinga.com/news/22/03/26148458/stocks-that-hit-52-week-lows-on-tuesday,ANNX,0.00539,Neutral,-0.038652
MiroBio Continues Expansion of Executive Leadership Team with Key Appointments to Advance Development of Checkpoint Agonist Antibodies for Autoimmune Disease,20220308T113000,https://www.benzinga.com/pressreleases/22/03/g26034189/mirobio-continues-expansion-of-executive-leadership-team-with-key-appointments-to-advance-developm,ANNX,0.046724,Somewhat-Bullish,0.170835
